Iodine-131 labelled octreotide: Not an option for somatostatin receptor therapy

European Journal of Nuclear Medicine

Volumn 23, Issue 7, 1996, Pages 775-781

  Bakker, Willem H ^a   Breeman, Wout A P ^a   Van Der Pluijm, Marcel E ^a   De Jong, Marion ^a   Visser, Theo J ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Peptide; Receptor; Therapy; Tumour

Indexed keywords

IODINE 131; OCTREOTIDE; PEPTIDE; RADIOISOTOPE; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER; DIAGNOSTIC VALUE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRRADIATION; PURIFICATION; RADIOIODINATION; RADIOLYSIS; RECEPTOR BINDING; SCINTIGRAPHY; TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; OCTREOTIDE; PENTETIC ACID; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0029934525     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00843706     Document Type: Article

References (34)

1. Bukker WH, Krenning HP, Breeman WA, Kooij PPM, Reubi JC, Koper JW, de Jong M, Lameris JS, Visser TJ, Lamberts SWJ. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumours in man. J Nucl Med 1991; 32: 1184-1189.
2. 3]-octreotide. J Nucl Med 1992; 33: 652-658.
3. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
4. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253-2263.
5. Virgolini I, Raderer M, Angelberger P, Banyai S, Scheithauer W, Valent P, Vasoactive intestinal peptide (VIP) receptor imaging in the localisation of intestinal adenocarcinomas and en-docrine tumors. J Nucl Med 1994; 5: 97P.
6. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging tor the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
7. Babich JW, Graham W, Barrow SA, Dragotakes SC, Tompkins DG, Rubin RH, Fischman AJ, Technetium-99m-labelled chemotactic peptides: comparison with indium-111-labelled white blood cells for localizing acute bacterial infection in the rabbit. J Nucl Med 1993; 34: 2176-2181.
8. Wolf H, Marschall F, Scheffold N, Clause M, Schramm M, Henze E, Iodine-123 labelling of atrial natriuretic peptide and its analogues: initial results. Eur J Nucl Med 1993; 20: 297-301.
9. Solomon HE, Derlan CK, Beblavy, Jester D, Santull R, Pike M, Kroon D, Hoey K, Fischman AJ. Focal infection imaging using an In-111 labelled antagonist chemotactic peptide. J Nucl Med 1994; 35: 45P.
10. 3]-oct-reotide. Eur J Nucl Med 1993; 20: 1089-1094.
11. Buxton-Thomas M, Ramage JK, Williams R, Comparison of indium-111-labelled octreotide and I-123-metaiodohenzyl-guanidine imaging in patient with secondary carcinoid tumours of the liver. Eur J Nucl Med 1994; 21(Suppl): 200.
12. Freitas JH, Gross MD, Ripley S, Shapiro B, Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 1985; 15: 106-131.
13. Hoefnagel CA, Radionuclide therapy revisited. Eur J Nucl Med 1991; 18: 408-431.
14. 1]-octreotide in humans. J Nucl Med 1994; 35: 226P.
15. 1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733: 496-506.
16. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PPM, Reubi JC, Klijn JG, Visser TJ, Doctor R, Lamberts SWJ. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31: 1501-1509.
17. Reubi JC, New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci 1985; 36: 1829-1836.
18. 111In-pentetreotide in rats. J Nucl Med 1995; 36: 623-627.
19. Dörr U, Räth U, Sautter-Bihl M-L, Guzman G, Bach D, Adrian H-J, Bihl H. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993; 20: 431-433.
20. Dörr U, Wurm K, Horing E, Guzman G, Räth U, Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogues. Horm Metab Res 1993; 27(Suppl): 36-43.
21. Becker W, Behr Th, Pavel M, Hensen J, Wolff F. In-111-Ocetreotid-Scintigraphie unter Somatostatintherapie. Nukl Med 1994; 33: 4986.
22. Soresi E, Bombardieri E, Chili A, Boffi R, Invernizzi G, Crippa F, Maffioli L. Indium-111-DTPA-octreotide seintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer. Tumori 1995; 81: 125-127.
23. Murty Goddu S. Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35: 303-316.
24. Jonkhoff AR, Huijgens PC, Versteegh RT, van Dieren EB, Ossenkoppele GJ, Martens HJM, Teule GJJ. Gallium-67 radiotoxicity in human U937 lymphoma cells. Br J Cancer 1993; 67: 693-700.
25. Jonkhoff AR, van Dieren EB, Huijgens PC, Versteegh RT, Dräger A, van der Loosdrecht AA, Teule GJJ. Biological effectiveness of 67-gallium decay in HL60 cells compared with external low dose rate gamma irradiation: effects on proliferation, G2 arrest, and clonogenic capacity. Int J Radiat Oncol Biol Phys 1994; 30: 117-124.
26. Van Leeuwen-Stok AE, Drager AM, Schuurhuis GJ, Platier AW, Teule GJJ, Huijgens PC. Gallium 67 in the human lymphoid cell line U-175: uptake, cytotoxicity and intracellular localization, Int J Radiat Biol 1993; 64: 749-759.
27. Goedemans WT, de Jong MTM, Deutz E, Miller KM, Brodack J, Ensing GJ. Development of an In-111 labelled somatostatin analogue: Octreoscan 111. Eur J Nucl Med 1991; 18: 532.
28. Behr TM, Sharkey RM, Juweid ME, Aninipot R, Mattes MJ, Stein R, Blumenthal RD, Griffiths GL, Goldenberg DM. Residualizing radiometals (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies. Eur J Nucl Med 1995; 8: 765P.
29. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, Colcher D. Comparative biodistributions of yttrium- and indium-labelled monoclonal antibody B72.3 in uthymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989; 30: 672-682.
30. Moi MK, Meares CF. The peptide way to macrocyclic bifunctional chelating agents: sysnthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and study of its yttrium(III) complex. J Am Chem Soc 1988; 110 : 6266-6267.
31. Stolz B, Smith-Jones PM, Ruser G, Albert R, Briner U, Mäcke H, Weckbecker G, Bruns C. Somatostatin receptor-mediated radiotherapy of cancer, preclinical evaluation of the concept. J Nucl Med 1995; 36: 114p.
32. Hosono M, Hosono MN, Haberberger T, Zamora PO, Guhlke S, Bender H, Knapp FF Jr, Biersack HJ. Imaging of small-cell lung cancer xenografts with I-125, In-111, and Re-188 octreotides. J Nucl Med 1995; 36: 72p.
33. 188Re-RC-160, a directly-radiolabelled somatostatin analogue. Int J Cancer 1996; 65: 214-220.
34. 1]-octreotide. Eur J Nucl Med 1995; 22: 608-616.